Singapore markets closed

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.9980+0.0080 (+0.40%)
At close: 08:00AM BST
Full screen
Loading interactive chart…
  • GlobeNewswire

    ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

    Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial in BPDStrengthening the IP position in CNS with formal notices of intention to grant in the EU and Korea for patent application covering the use of vafidemstat to treat aggression and social withdrawalContinues to recruit patients in FRIDA trial with iadademstat i

  • GlobeNewswire

    ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

    Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European

  • GlobeNewswire

    ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

    In combination with either atezolizumab or durvalumabMADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune checkp